|
KMID : 0869620170340030275
|
|
Journal of Korean Society of Hospital Pharmacists
2017 Volume.34 No. 3 p.275 ~ p.283
|
|
|
Evaluation of Adverse Drug Reaction of Antiviral Therapy for Middle East Respiratory Syndrome Coronavirus Infection
|
|
Park So-Jin
Sohn You-Min
Park Hyo-Jung
In Yong-Won
Lee Su-Mi
Lee Yong-Seok
Lee Young-Mee
|
|
|
Abstract
|
|
|
Background : Treatment experiences with antiviral agents against MERS-CoV (Middle East Respiratory Syndrome Coronavirus) infection are limited, and there is lack of information regarding adverse drug reactions (ADRs) in this patient group. In 2015, we evaluated the ADRs of antiviral treatment against MERS-CoV infections in one tertiary teaching hospital in South Korea.
Methods : Between May 20th and July 20th 2015, a retrospective chart review was conducted to evaluate any ADRs. We focused on three antiviral agents: ribavirin, peginterferon alpha2a and lopinavir/ritonavir. Laboratory data and clinical implications of ADRs were collected through electronic medical records. The ADRs were evaluated and cross checked by three independent pharmacists.
Results : Totally, 28 patients were evaluated, and 15 ADRs were detected. Ribavirin was the most causative agent. Hematologic ADRs were the maximum reported, and nausea/vomiting was second ranked. Seven ADRs were scored as Grade 3 severity of ADRs, as per the CTCAE ver. 4.0; the causative drug was discontinued in 9 cases. Causality scores using WHO-UMC and Naranjo scale indicated that most of the ADR cases had a‘ possible’relationship.
Conclusion : ADR patterns of the three drugs evaluated for MERS-CoV patients were mostly similar with the limited existing reports.
|
|
|
KEYWORD
|
|
|
MERS-CoV, ADR (adverse drug reaction), Antiviral therapy
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|